Luxna Biotech Co., Ltd. – Trademark Portfolio
Entity Type: 03
Luxna Biotech Co., Ltd. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include 5'-CP and LUXNA BIOTECH.
2-8, Yamadaoka,
Suita-shi Osaka 565-0871
Showing of trademarks Trademarks
Trademark Classifications
Luxna Biotech Co., Ltd.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Luxna Biotech Co., Ltd. have?
Luxna Biotech Co., Ltd. has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned.
What trademark classes does Luxna Biotech Co., Ltd. file in?
Luxna Biotech Co., Ltd. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Luxna Biotech Co., Ltd.'s most well-known trademarks?
Luxna Biotech Co., Ltd.'s registered trademark portfolio includes well-known marks such as 5'-CP and LUXNA BIOTECH. These are among 3 currently registered trademarks in the portfolio.
What is Luxna Biotech Co., Ltd.'s trademark registration success rate?
Luxna Biotech Co., Ltd. has a 43% trademark registration rate, with 3 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.